The Professional Guinea Pig: Big Pharma and the Risky World of Human Subjects
The Professional Guinea Pig documents the emergence of the professional research subject in Phase I clinical trials testing the safety of drugs in development. Until the mid-1970s Phase I trials were conducted on prisoners. After that practice was outlawed, the pharmaceutical industry needed a repla...
Gespeichert in:
| 1. Verfasser: | |
|---|---|
| Format: | Elektronisch E-Book |
| Sprache: | English |
| Veröffentlicht: |
Durham
Duke University Press
[2010]
|
| Schlagworte: | |
| Online-Zugang: | DE-1043 DE-1046 DE-859 DE-860 DE-473 DE-703 DE-739 DE-858 URL des Erstveröffentlichers |
| Zusammenfassung: | The Professional Guinea Pig documents the emergence of the professional research subject in Phase I clinical trials testing the safety of drugs in development. Until the mid-1970s Phase I trials were conducted on prisoners. After that practice was outlawed, the pharmaceutical industry needed a replacement population and began to aggressively recruit healthy, paid subjects, some of whom came to depend on the income, earning their living by continuously taking part in these trials. Drawing on ethnographic research among self-identified "professional guinea pigs" in Philadelphia, Roberto Abadie examines their experiences and views on the conduct of the trials and the risks they assume by participating. Some of the research subjects he met had taken part in more than eighty Phase I trials. While the professional guinea pigs tended to believe that most clinical trials pose only a moderate health risk, Abadie contends that the hazards presented by continuous participation, such as exposure to potentially dangerous drug interactions, are discounted or ignored by research subjects in need of money. The risks to professional guinea pigs are also disregarded by the pharmaceutical industry, which has become dependent on the routine participation of experienced research subjects. Arguing that financial incentives compromise the ethical imperative for informed consent to be freely given by clinical-trials subjects, Abadie confirms the need to reform policies regulating the participation of paid subjects in Phase I clinical trials |
| Beschreibung: | Description based on online resource; title from PDF title page (publisher's Web site, viewed 28. Okt 2020) |
| Beschreibung: | 1 online resource (197 pages) |
| ISBN: | 9780822393245 |
| DOI: | 10.1515/9780822393245 |
Internformat
MARC
| LEADER | 00000nam a2200000zc 4500 | ||
|---|---|---|---|
| 001 | BV047049108 | ||
| 003 | DE-604 | ||
| 005 | 20201210 | ||
| 007 | cr|uuu---uuuuu | ||
| 008 | 201207s2010 xx o|||| 00||| eng d | ||
| 020 | |a 9780822393245 |9 978-0-8223-9324-5 | ||
| 024 | 7 | |a 10.1515/9780822393245 |2 doi | |
| 035 | |a (ZDB-23-DGG)9780822393245 | ||
| 035 | |a (OCoLC)1226704466 | ||
| 035 | |a (DE-599)BVBBV047049108 | ||
| 040 | |a DE-604 |b ger |e rda | ||
| 041 | 0 | |a eng | |
| 049 | |a DE-1046 |a DE-859 |a DE-860 |a DE-473 |a DE-739 |a DE-1043 |a DE-703 |a DE-858 | ||
| 082 | 0 | |a 615/.19 |2 22 | |
| 100 | 1 | |a Abadie, Roberto |e Verfasser |4 aut | |
| 245 | 1 | 0 | |a The Professional Guinea Pig |b Big Pharma and the Risky World of Human Subjects |c Roberto Abadie |
| 264 | 1 | |a Durham |b Duke University Press |c [2010] | |
| 264 | 4 | |c © 2010 | |
| 300 | |a 1 online resource (197 pages) | ||
| 336 | |b txt |2 rdacontent | ||
| 337 | |b c |2 rdamedia | ||
| 338 | |b cr |2 rdacarrier | ||
| 500 | |a Description based on online resource; title from PDF title page (publisher's Web site, viewed 28. Okt 2020) | ||
| 520 | |a The Professional Guinea Pig documents the emergence of the professional research subject in Phase I clinical trials testing the safety of drugs in development. Until the mid-1970s Phase I trials were conducted on prisoners. After that practice was outlawed, the pharmaceutical industry needed a replacement population and began to aggressively recruit healthy, paid subjects, some of whom came to depend on the income, earning their living by continuously taking part in these trials. Drawing on ethnographic research among self-identified "professional guinea pigs" in Philadelphia, Roberto Abadie examines their experiences and views on the conduct of the trials and the risks they assume by participating. Some of the research subjects he met had taken part in more than eighty Phase I trials. While the professional guinea pigs tended to believe that most clinical trials pose only a moderate health risk, Abadie contends that the hazards presented by continuous participation, such as exposure to potentially dangerous drug interactions, are discounted or ignored by research subjects in need of money. The risks to professional guinea pigs are also disregarded by the pharmaceutical industry, which has become dependent on the routine participation of experienced research subjects. Arguing that financial incentives compromise the ethical imperative for informed consent to be freely given by clinical-trials subjects, Abadie confirms the need to reform policies regulating the participation of paid subjects in Phase I clinical trials | ||
| 546 | |a In English | ||
| 650 | 7 | |a SOCIAL SCIENCE / Anthropology / Cultural & Social |2 bisacsh | |
| 650 | 4 | |a Drugs |x Testing | |
| 650 | 4 | |a Drugs |z United States |x Testing | |
| 650 | 4 | |a Human experimentation in medicine |z United States | |
| 856 | 4 | 0 | |u https://doi.org/10.1515/9780822393245 |x Verlag |z URL des Erstveröffentlichers |3 Volltext |
| 912 | |a ZDB-198-DUA | ||
| 912 | |a ZDB-23-DGG | ||
| 943 | 1 | |a oai:aleph.bib-bvb.de:BVB01-032456504 | |
| 966 | e | |u https://doi.org/10.1515/9780822393245 |l DE-1043 |p ZDB-23-DGG |q FAB_PDA_DGG |x Verlag |3 Volltext | |
| 966 | e | |u https://doi.org/10.1515/9780822393245 |l DE-1046 |p ZDB-23-DGG |q FAW_PDA_DGG |x Verlag |3 Volltext | |
| 966 | e | |u https://doi.org/10.1515/9780822393245 |l DE-859 |p ZDB-23-DGG |q FKE_PDA_DGG |x Verlag |3 Volltext | |
| 966 | e | |u https://doi.org/10.1515/9780822393245 |l DE-860 |p ZDB-23-DGG |q FLA_PDA_DGG |x Verlag |3 Volltext | |
| 966 | e | |u https://doi.org/10.1515/9780822393245 |l DE-473 |p ZDB-23-DGG |q UBG_PDA_DGG |x Verlag |3 Volltext | |
| 966 | e | |u https://doi.org/10.1215/9780822393245 |l DE-703 |p ZDB-198-DUA |x Verlag |3 Volltext | |
| 966 | e | |u https://doi.org/10.1515/9780822393245 |l DE-739 |p ZDB-23-DGG |q UPA_PDA_DGG |x Verlag |3 Volltext | |
| 966 | e | |u https://doi.org/10.1515/9780822393245 |l DE-858 |p ZDB-23-DGG |q FCO_PDA_DGG |x Verlag |3 Volltext | |
Datensatz im Suchindex
| _version_ | 1824507749889736704 |
|---|---|
| adam_text | |
| adam_txt | |
| any_adam_object | |
| any_adam_object_boolean | |
| author | Abadie, Roberto |
| author_facet | Abadie, Roberto |
| author_role | aut |
| author_sort | Abadie, Roberto |
| author_variant | r a ra |
| building | Verbundindex |
| bvnumber | BV047049108 |
| collection | ZDB-198-DUA ZDB-23-DGG |
| ctrlnum | (ZDB-23-DGG)9780822393245 (OCoLC)1226704466 (DE-599)BVBBV047049108 |
| dewey-full | 615/.19 |
| dewey-hundreds | 600 - Technology (Applied sciences) |
| dewey-ones | 615 - Pharmacology and therapeutics |
| dewey-raw | 615/.19 |
| dewey-search | 615/.19 |
| dewey-sort | 3615 219 |
| dewey-tens | 610 - Medicine and health |
| discipline | Medizin |
| discipline_str_mv | Medizin |
| doi_str_mv | 10.1515/9780822393245 |
| format | Electronic eBook |
| fullrecord | <?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>00000nam a2200000zc 4500</leader><controlfield tag="001">BV047049108</controlfield><controlfield tag="003">DE-604</controlfield><controlfield tag="005">20201210</controlfield><controlfield tag="007">cr|uuu---uuuuu</controlfield><controlfield tag="008">201207s2010 xx o|||| 00||| eng d</controlfield><datafield tag="020" ind1=" " ind2=" "><subfield code="a">9780822393245</subfield><subfield code="9">978-0-8223-9324-5</subfield></datafield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1515/9780822393245</subfield><subfield code="2">doi</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(ZDB-23-DGG)9780822393245</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(OCoLC)1226704466</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-599)BVBBV047049108</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-604</subfield><subfield code="b">ger</subfield><subfield code="e">rda</subfield></datafield><datafield tag="041" ind1="0" ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="049" ind1=" " ind2=" "><subfield code="a">DE-1046</subfield><subfield code="a">DE-859</subfield><subfield code="a">DE-860</subfield><subfield code="a">DE-473</subfield><subfield code="a">DE-739</subfield><subfield code="a">DE-1043</subfield><subfield code="a">DE-703</subfield><subfield code="a">DE-858</subfield></datafield><datafield tag="082" ind1="0" ind2=" "><subfield code="a">615/.19</subfield><subfield code="2">22</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Abadie, Roberto</subfield><subfield code="e">Verfasser</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">The Professional Guinea Pig</subfield><subfield code="b">Big Pharma and the Risky World of Human Subjects</subfield><subfield code="c">Roberto Abadie</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="a">Durham</subfield><subfield code="b">Duke University Press</subfield><subfield code="c">[2010]</subfield></datafield><datafield tag="264" ind1=" " ind2="4"><subfield code="c">© 2010</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">1 online resource (197 pages)</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="500" ind1=" " ind2=" "><subfield code="a">Description based on online resource; title from PDF title page (publisher's Web site, viewed 28. Okt 2020)</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">The Professional Guinea Pig documents the emergence of the professional research subject in Phase I clinical trials testing the safety of drugs in development. Until the mid-1970s Phase I trials were conducted on prisoners. After that practice was outlawed, the pharmaceutical industry needed a replacement population and began to aggressively recruit healthy, paid subjects, some of whom came to depend on the income, earning their living by continuously taking part in these trials. Drawing on ethnographic research among self-identified "professional guinea pigs" in Philadelphia, Roberto Abadie examines their experiences and views on the conduct of the trials and the risks they assume by participating. Some of the research subjects he met had taken part in more than eighty Phase I trials. While the professional guinea pigs tended to believe that most clinical trials pose only a moderate health risk, Abadie contends that the hazards presented by continuous participation, such as exposure to potentially dangerous drug interactions, are discounted or ignored by research subjects in need of money. The risks to professional guinea pigs are also disregarded by the pharmaceutical industry, which has become dependent on the routine participation of experienced research subjects. Arguing that financial incentives compromise the ethical imperative for informed consent to be freely given by clinical-trials subjects, Abadie confirms the need to reform policies regulating the participation of paid subjects in Phase I clinical trials</subfield></datafield><datafield tag="546" ind1=" " ind2=" "><subfield code="a">In English</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">SOCIAL SCIENCE / Anthropology / Cultural & Social</subfield><subfield code="2">bisacsh</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Drugs</subfield><subfield code="x">Testing</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Drugs</subfield><subfield code="z">United States</subfield><subfield code="x">Testing</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Human experimentation in medicine</subfield><subfield code="z">United States</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.1515/9780822393245</subfield><subfield code="x">Verlag</subfield><subfield code="z">URL des Erstveröffentlichers</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">ZDB-198-DUA</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">ZDB-23-DGG</subfield></datafield><datafield tag="943" ind1="1" ind2=" "><subfield code="a">oai:aleph.bib-bvb.de:BVB01-032456504</subfield></datafield><datafield tag="966" ind1="e" ind2=" "><subfield code="u">https://doi.org/10.1515/9780822393245</subfield><subfield code="l">DE-1043</subfield><subfield code="p">ZDB-23-DGG</subfield><subfield code="q">FAB_PDA_DGG</subfield><subfield code="x">Verlag</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="966" ind1="e" ind2=" "><subfield code="u">https://doi.org/10.1515/9780822393245</subfield><subfield code="l">DE-1046</subfield><subfield code="p">ZDB-23-DGG</subfield><subfield code="q">FAW_PDA_DGG</subfield><subfield code="x">Verlag</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="966" ind1="e" ind2=" "><subfield code="u">https://doi.org/10.1515/9780822393245</subfield><subfield code="l">DE-859</subfield><subfield code="p">ZDB-23-DGG</subfield><subfield code="q">FKE_PDA_DGG</subfield><subfield code="x">Verlag</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="966" ind1="e" ind2=" "><subfield code="u">https://doi.org/10.1515/9780822393245</subfield><subfield code="l">DE-860</subfield><subfield code="p">ZDB-23-DGG</subfield><subfield code="q">FLA_PDA_DGG</subfield><subfield code="x">Verlag</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="966" ind1="e" ind2=" "><subfield code="u">https://doi.org/10.1515/9780822393245</subfield><subfield code="l">DE-473</subfield><subfield code="p">ZDB-23-DGG</subfield><subfield code="q">UBG_PDA_DGG</subfield><subfield code="x">Verlag</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="966" ind1="e" ind2=" "><subfield code="u">https://doi.org/10.1215/9780822393245</subfield><subfield code="l">DE-703</subfield><subfield code="p">ZDB-198-DUA</subfield><subfield code="x">Verlag</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="966" ind1="e" ind2=" "><subfield code="u">https://doi.org/10.1515/9780822393245</subfield><subfield code="l">DE-739</subfield><subfield code="p">ZDB-23-DGG</subfield><subfield code="q">UPA_PDA_DGG</subfield><subfield code="x">Verlag</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="966" ind1="e" ind2=" "><subfield code="u">https://doi.org/10.1515/9780822393245</subfield><subfield code="l">DE-858</subfield><subfield code="p">ZDB-23-DGG</subfield><subfield code="q">FCO_PDA_DGG</subfield><subfield code="x">Verlag</subfield><subfield code="3">Volltext</subfield></datafield></record></collection> |
| id | DE-604.BV047049108 |
| illustrated | Not Illustrated |
| index_date | 2024-07-03T16:07:30Z |
| indexdate | 2025-02-19T17:29:41Z |
| institution | BVB |
| isbn | 9780822393245 |
| language | English |
| oai_aleph_id | oai:aleph.bib-bvb.de:BVB01-032456504 |
| oclc_num | 1226704466 |
| open_access_boolean | |
| owner | DE-1046 DE-859 DE-860 DE-473 DE-BY-UBG DE-739 DE-1043 DE-703 DE-858 |
| owner_facet | DE-1046 DE-859 DE-860 DE-473 DE-BY-UBG DE-739 DE-1043 DE-703 DE-858 |
| physical | 1 online resource (197 pages) |
| psigel | ZDB-198-DUA ZDB-23-DGG ZDB-23-DGG FAB_PDA_DGG ZDB-23-DGG FAW_PDA_DGG ZDB-23-DGG FKE_PDA_DGG ZDB-23-DGG FLA_PDA_DGG ZDB-23-DGG UBG_PDA_DGG ZDB-23-DGG UPA_PDA_DGG ZDB-23-DGG FCO_PDA_DGG |
| publishDate | 2010 |
| publishDateSearch | 2010 |
| publishDateSort | 2010 |
| publisher | Duke University Press |
| record_format | marc |
| spelling | Abadie, Roberto Verfasser aut The Professional Guinea Pig Big Pharma and the Risky World of Human Subjects Roberto Abadie Durham Duke University Press [2010] © 2010 1 online resource (197 pages) txt rdacontent c rdamedia cr rdacarrier Description based on online resource; title from PDF title page (publisher's Web site, viewed 28. Okt 2020) The Professional Guinea Pig documents the emergence of the professional research subject in Phase I clinical trials testing the safety of drugs in development. Until the mid-1970s Phase I trials were conducted on prisoners. After that practice was outlawed, the pharmaceutical industry needed a replacement population and began to aggressively recruit healthy, paid subjects, some of whom came to depend on the income, earning their living by continuously taking part in these trials. Drawing on ethnographic research among self-identified "professional guinea pigs" in Philadelphia, Roberto Abadie examines their experiences and views on the conduct of the trials and the risks they assume by participating. Some of the research subjects he met had taken part in more than eighty Phase I trials. While the professional guinea pigs tended to believe that most clinical trials pose only a moderate health risk, Abadie contends that the hazards presented by continuous participation, such as exposure to potentially dangerous drug interactions, are discounted or ignored by research subjects in need of money. The risks to professional guinea pigs are also disregarded by the pharmaceutical industry, which has become dependent on the routine participation of experienced research subjects. Arguing that financial incentives compromise the ethical imperative for informed consent to be freely given by clinical-trials subjects, Abadie confirms the need to reform policies regulating the participation of paid subjects in Phase I clinical trials In English SOCIAL SCIENCE / Anthropology / Cultural & Social bisacsh Drugs Testing Drugs United States Testing Human experimentation in medicine United States https://doi.org/10.1515/9780822393245 Verlag URL des Erstveröffentlichers Volltext |
| spellingShingle | Abadie, Roberto The Professional Guinea Pig Big Pharma and the Risky World of Human Subjects SOCIAL SCIENCE / Anthropology / Cultural & Social bisacsh Drugs Testing Drugs United States Testing Human experimentation in medicine United States |
| title | The Professional Guinea Pig Big Pharma and the Risky World of Human Subjects |
| title_auth | The Professional Guinea Pig Big Pharma and the Risky World of Human Subjects |
| title_exact_search | The Professional Guinea Pig Big Pharma and the Risky World of Human Subjects |
| title_exact_search_txtP | The Professional Guinea Pig Big Pharma and the Risky World of Human Subjects |
| title_full | The Professional Guinea Pig Big Pharma and the Risky World of Human Subjects Roberto Abadie |
| title_fullStr | The Professional Guinea Pig Big Pharma and the Risky World of Human Subjects Roberto Abadie |
| title_full_unstemmed | The Professional Guinea Pig Big Pharma and the Risky World of Human Subjects Roberto Abadie |
| title_short | The Professional Guinea Pig |
| title_sort | the professional guinea pig big pharma and the risky world of human subjects |
| title_sub | Big Pharma and the Risky World of Human Subjects |
| topic | SOCIAL SCIENCE / Anthropology / Cultural & Social bisacsh Drugs Testing Drugs United States Testing Human experimentation in medicine United States |
| topic_facet | SOCIAL SCIENCE / Anthropology / Cultural & Social Drugs Testing Drugs United States Testing Human experimentation in medicine United States |
| url | https://doi.org/10.1515/9780822393245 |
| work_keys_str_mv | AT abadieroberto theprofessionalguineapigbigpharmaandtheriskyworldofhumansubjects |